@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://bio2rdf.org/drugbank_resource:DB00055_DB08813_nanopub.RAlYC0dLFL2Nm0jMvF5rYaf-wnVUu2_vfnz4DIUSMpzh0> .
@prefix sub: <http://bio2rdf.org/drugbank_resource:DB00055_DB08813_nanopub.RAlYC0dLFL2Nm0jMvF5rYaf-wnVUu2_vfnz4DIUSMpzh0#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix has-source: <http://semanticscience.org/resource/SIO_000253> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix npx: <http://purl.org/nanopub/x/> .
sub:head {
   this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:publicationInfo ;
    a np:Nanopublication .
}
sub:assertion {
   d:DB00055 dv:ddi-interactor-in dr:DB00055_DB08813 .
  d:DB08813 dv:ddi-interactor-in dr:DB00055_DB08813 .
  dr:DB00055_DB08813 dcterms:identifier "drugbank_resource:DB00055_DB08813" ;
    dcterms:title "DDI between Drotrecogin alfa and Nadroparin - The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin."@en ;
    a dv:Drug-Drug-Interaction ;
    rdfs:label "DDI between Drotrecogin alfa and Nadroparin - The potential benefits of drotrecogin alfa should be weighed against an increased risk of bleeding in patients receiving therapeutic doses of low molecular weight heparins such as nadroparin. Monitor for bleeding during concomitant therapy, and immediately stop infusion of drotrecogin if clinically important bleeding occurs. In patients receiving prophylactic heparin doses, consider continuing this during drotrecogin.  [drugbank_resource:DB00055_DB08813]"@en .
}
sub:provenance {
   sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}
sub:publicationInfo {
   sub:signature.MCwCFCsEJUQJWpBx npx:hasPublicKey "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" ;
    npx:hasSignature "MCwCFCsEJUQJWpBx5JDzUSCWduj5H0ejAhRvcnngZh1rkPtfnTFer+SE6RB1Ow==" ;
    npx:signedBy instance: .
  this: dcterms:created "2018-03-30T11:12:33.331+02:00"^^xsd:dateTime ;
    dcterms:license <https://creativecommons.org/licenses/by-nc/4.0/> ;
    npx:hasSignatureElement sub:signature.MCwCFCsEJUQJWpBx ;
    prov:wasGeneratedBy process: .
  instance: prov:specializationOf codebase: ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11" ;
    prov:used version: ;
    prov:wasAssociatedWith instance: ;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  version: dcterms:isVersionOf codebase: ;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349" ;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}